Crossref
Is Primary Tumor Size Still the Main Barrier to Active Surveillance?
Clinical Thyroidology® · 01.08.2026 · 38 (8) · 282-285
DOI: 10.1177/23299711261475848 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Thyroidology®, online erschienen am 10.08.2026. Verfasst von Fernanda Vaisman. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Vaisman, F. (2026). Is Primary Tumor Size Still the Main Barrier to Active Surveillance?. Clinical Thyroidology®, 38(8), 282-285. https://doi.org/10.1177/23299711261475848
Vancouver
Vaisman F. Is Primary Tumor Size Still the Main Barrier to Active Surveillance?. Clinical Thyroidology®. 2026;38(8):282-285. doi:10.1177/23299711261475848
BibTeX
@article{Vaisman2026,
author = {Vaisman, Fernanda},
title = {Is Primary Tumor Size Still the Main Barrier to Active Surveillance?},
journal = {Clinical Thyroidology®},
year = {2026},
volume = {38},
number = {8},
pages = {282--285},
doi = {10.1177/23299711261475848}
}
EUVIMED